ArticleFrontiers in oncology2026
Persistent endometrial dysfunction after fertility-sparing treatment for endometrial carcinoma: insights from donor oocyte cycles.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fertility-sparing treatment (FST) is an accepted option for selected women with endometrial carcinoma (EC) or atypical endometrial hyperplasia (AEH) wishing to preserve fertility. However, the impact of FST on subsequent endometrial function remains poorly understood. Oocyte donation (OD) offers a unique model to evaluate endometrial receptivity independently of oocyte quality. We assessed reproductive outcomes after OD in women aged ≥40 years with a history of FST for EC or AEH. Methods: This retrospective case series included women aged ≥40 years with histologically confirmed Endometrioid endometrial carcinoma (EEC) or AEH who achieved complete response after FST and subsequently underwent blastocyst transfer through OD. All cycles involved vitrified-warmed donor oocytes, intracytoplasmic sperm injection, blastocyst culture, and elective single embryo transfer. The primary outcome was live birth rate (LBR) per embryo transfer. Results: Sixteen patients underwent 27 embryo transfer cycles. Median age at first transfer was 45.5 years. Embryological outcomes were excellent, with a 96.8% oocyte survival rate and 80.4% top-quality blastocysts. Despite adequate endometrial preparation in all cases, reproductive outcomes were poor. The cumulative LBR per embryo transfer was 18.5% (5/27), while the cumulative LBR per patient was 31.2% (5/16). Patients with disease recurrence showed lower live birth rates than those without recurrence. Endometrial thickness was not associated with implantation outcomes. Conclusion: Women aged ≥40 years undergoing OD after FST for EC or AEH experience reduced reproductive success despite optimal embryo quality. These findings are consistent with the hypothesis of persistent endometrial dysfunction after FST and highlight the need for improved assessment of endometrial receptivity and timely integration of assisted reproductive treatment following complete response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.